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Abstract

clinical trials. Using an expert panel from the FM workshop of
the Outcome Measures in Rheumatology (OMERACT), a list
of potential objective measures was first developed. Studies
evaluating the measures were then methodically compiled by
systematic review of the literature using a search for FM and
the specific objective measure of interest. The databases
searched included MEDLINE (1966 to 2006), PubMed
(1966 to 2006), CINAHL (1982 to 2006), EMBASE (1988
to 2006), Healthstar (1975 to 2000), Current Contents
(2000 to 2006), Web of Science (1980 to 2006), PsychInfo
(1887 to 2006), Science Citation Indexes (1996 to 2006),
and/or Cochrane Collaboration Reviews (1993 to 2006). The
resulting published studies were used as the basis for the
review.

Researchers studying fibromyalgia strive to identify objective,
measurable biomarkers that may identify susceptible individuals,
may facilitate diagnosis, or that parallel activity of the disease.
Candidate objective measures range from sophisticated functional
neuroimaging to office-ready measures of the pressure pain
threshold. A systematic literature review was completed to assess
highly investigated, objective measures used in fibromyalgia
studies. To date, only experimental pain testing has been shown to
coincide with improvements in clinical status in a longitudinal
study. Concerted efforts to systematically evaluate additional
objective measures in research trials will be vital for ongoing
progress in outcome research and translation into clinical practice.

Introduction
Fibromyalgia (FM) is a chronic condition characterized by
widespread pain and tenderness on examination, along with
symptoms of nonrestorative sleep, fatigue, and cognitive
difficulties. Recent familial studies have suggested an
underlying genetic susceptibility on which environmental
factors trigger the expression of symptoms [1,2]. Despite the
myalgias that patients experience, no abnormality in muscle
has been reliably found [3]. Instead, aberrant pain and sensory processing probably caused by alterations in the central
nervous system function are being consistently recognized in
FM and related syndromes. Investigations into the autonomic
nervous system and the hypothalamic–pituitary–adrenal axis
also suggest a role of these stress–response systems in
vulnerability to FM or in symptom expression in FM.
Our improved understanding of FM has stimulated the search
for biomarkers to be used to identify individuals susceptible
to the syndrome, for the diagnosis of FM, for objective
measures of disease activity, or as surrogate endpoints of

Genetics
Increasing evidence supports a genetic predisposition to FM.
First-degree relatives of individuals with FM display an
eightfold greater risk of developing the syndrome than those
in the general population [1]. As such, a genetic study using
multicase families has been completed that identified an HLA
linkage not yet replicated [4].
Polymorphisms in the serotonergic 5-hydroxy tryptamine 2A
receptor (T/T phenotype), the serotonin transporter, the
dopamine 4 receptor and the catecholamine o-methyl transferase enzyme have also been evaluated in patients with FM
[5-10]. Notably, these polymorphisms all affect the
metabolism or transport of monoamines, compounds that
have a critical role in both sensory processing and the human
stress response. With the exception of the catecholamine omethyl transferase finding and the dopamine-4-receptor gene
polymorphism, however, which have not been replicated or

DNIC = diffuse noxious inhibitory control; ERP = event-related potential; FM = fibromyalgia; fMRI = functional magnetic resonance imaging; IL =
interleukin; SPECT = single-photon emission computed tomography.
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Table 1
Genetics in fibromyalgia

Year of
study

Number of
subjects

Number of
control
individuals

Bondy and
colleagues [5]

1999

168 FMS

Gürsoy and
colleagues [6]

2001

Gürsoy and
colleagues [7]

Reference

Objective measure

Findings

115

5-HT2A, T102C polymorphism

Different from control, but not significant
for specific allele

58 FMS

58

5-HT2A, T102C polymorphism

Not significant

2003

61 FMS

61

COMT haplotype

Over-representation of LL variant (low
activity). Similar to migraine and TMD

Offenbaecher
and colleagues [8]

1999

62 FMS

110

5-HTT

One positive for over-representative SS
genotype, one negative study. Suggestion
that any association might be related to
comorbid psychology

Gürsoy [9]

2002

53 FMS

60 mentally
healthy

5-HTT

Yunus and
colleagues [4]

1999

40 multicase
families

Buskila and
colleagues [10]

2004

HLA

Linkage to HLA

Dopamine D4 receptor
polymorphism

Decrease in the frequency of the sevenrepeat allele in exon III of the D4 receptor
gene associated with fibromyalgia. Finding
associated with low novelty-seeking
personality

COMT, catecholamine o-methyl transferase; FMS, fibromyalgia syndrome; 5-HT2A, serotonergic 5-hydroxytryptamine 2A receptor (T/T phenotype);
5-HTT, serotonin transporter; TMD, temporomandibular disorder.

refuted, the other findings initially noted were generally not
found in subsequent studies [4-10]. In some cases, the
findings in FM were found when all individuals with this
disorder were studied, but not when individuals free of
psychiatric comorbidities were studied, suggesting that some
of the above findings may track more closely with psychiatric
comorbidity than inherent features of FM. Other candidate
genes evaluated but not shown to be associated with FM are
presented in Table 1.

have assessed the pain threshold and have attempted to
quantify the pain experience in FM. A review of the investigated modalities gives the greatest support for the use of the
tender point intensity/index, pressure pain thresholds, or heat
pain thresholds as objective measures of the degree of
hyperalgesia (increased pain to normally painful stimuli) and
allodynia (pain in response to normally nonpainful stimuli) of
an individual. Another consistent finding has been an
absence of descending endogenous analgesic activity in FM.

Evoked (experimental) pain measures

Tender point count
The American College of Rheumatology criteria for FM require
that an individual has a certain degree of tenderness. A
tender point count is performed by applying 4 kg pressure
manually to 18 predefined tender points, and then asking the
patient whether these areas are tender. A positive response
is considered a tender point; if an individual has 11 tender
points or more, this element of the case definition is satisfied.

Even before the establishment of the American College of
Rheumatology criteria for FM in 1990, which require both
widespread pain and tenderness, investigators have used
psychophysical pain testing to learn more about the nature of
this condition. In fact, the early findings that the tenderness in
FM was detectable throughout the body, rather than just
confined to areas of tender points or muscle, was a hallmark
finding that led investigators to believe this was a central
nervous system pain amplification syndrome [11]. These
measures are only relatively objective since they require patient
self-report, but tender points do clearly measure a phenomenon that is independent from spontaneous, clinical pain.
Numerous experimental pain studies have evaluated methods
of quantifying the sensory experience of pain. Various groups
using an assortment of devices that produce several stimuli
Page 2 of 18
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The apparent close link between tenderness and FM has
been well studied in both clinical trials of new therapies and
in mechanistic studies. In a number of longitudinal randomized, placebo-controlled trials, improvements in clinical pain
have corresponded with a significant change in tender point
counts or in the tender point index [12-14]. In contrast, other
studies did not show a correspondence between improvements in clinical pain and tender point counts [15-20].
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The discrepancies between studies could either be because
the therapies did not improve tenderness or because tender
points are not a good measure of tenderness. Both factors
are likely to play a role since, in certain studies where multiple
measures of the pain threshold were used, tender point
counts did not significantly improve whereas other measures
did [21,22]. Moreover, other studies have shown that tender
points are not a pure measure of tenderness. For example,
there is a strong correlation between tender point counts and
measures of distress in population-based studies [23].
Tender points have also been demonstrated to be biased by
cognitive and emotional aspects of pain perception, whereas
other measures of tenderness are much less so (see below)
[24]. Improvements in tender point counts in some previous
FM trials therefore possibly occurred because of improvements in distress, rather than because of inherent improvements in pressure pain threshold. Finally, tender points are
often not continuously distributed in samples; rather, most
people have either very few or nearly 18 tender points. As
such, many investigators do not feel that tender point counts
are useful to assess tenderness, and have instead turned to
psychophysically and statistically superior measures.
Pressure pain thresholds
Directly measuring pressure pain thresholds is an alternative
method of documenting tenderness. Devices that measure
pressure pain thresholds have been used to demonstrate a
left-shift and lowered pressure pain thresholds in patients
with FM compared with control individuals, and this finding is
noted anywhere in the body, both at tender points and in
areas previously considered control points (Table 2). These
findings suggest to many investigators that the term control
points should be abandoned, or replaced by a term such as
high-threshold tender point, since FM patients are just as
tender in these regions relative to healthy control individuals.

Many of these studies initially used commercial devices or
dolorimeters to deliver continuously increasing pressure via
blunt probes. These measures were found to be sensitive to
psychophysical and psychological biases, however, slightly
similar to tender point counts using digital palpation
(reviewed in [25]). For instance, the rate of increase of
stimulus pressure, controlled by the operator, and patient
distress were both shown to influence the pain threshold
[24,26]. To minimize the bias, more sophisticated paradigms
using random delivery of pressures have been developed and
investigated [27,28] (Table 3). Random delivery may be less
sensitive to certain influences, but it is not free of bias. For
instance, in a study by Petzke and colleagues, FM patients
reported higher pain during random delivery than during
ascending – possibly due to a perceived lack of control [28].
A recent longitudinal study compared the three different
evoked measures – tender point counts, the dolorimeter
(ascending pressure paradigm), and the multiple random
staircase (random pressure paradigm) – with clinical reports

of pain improvement [21]. Although both clinical pain
measures improved during the course of the study involving
acupuncture, only one of the evoked measures – the multiple
random staircase measure, which presented stimuli to
individuals in an unpredictable fashion – improved after
treatment. These results suggest that, of the different
methods, the random stimuli paradigm may be more likely to
systematically change over time. Interpretation of the results
is nonetheless limited and will need to be reproduced and
examined using other treatment modalities.
Heat, cold, and electrical stimuli
In addition to the heightened sensitivity to pressure noted in
FM, other types of painful stimuli also are judged more painful
by these patients. A decreased heat pain threshold in FM
patients as compared with control individuals has been
shown by multiple groups [28-30] (Table 4). A reduced cold
pain threshold has been reported by one group in two
different studies [30,31]. Sensitivity to warmth and the ability
to detect electrical stimuli do not appear to be discriminative
measures at this time.
Diminished diffuse noxious inhibitory control
In the process of understanding altered evoked pain sensitivity present in FM, evaluation of the intrinsic analgesic
systems has uncovered another potential biomarker:
diminished diffuse noxious inhibitory control (DNIC). DNIC
testing in both animals and humans involves testing the pain
threshold at baseline, and then administering an acutely
painful stimulus that leads to a systemic analgesic effect,
presumably by activating endogenous analgesic systems.

Several studies by different groups, using different conditioning stimuli (the acute noxious stimulus) and test stimuli
(the stimulus used to measure pain threshold at baseline and
following the acute, noxious stimulus), have indicated a
deficiency of DNIC in individuals with FM. Diminished DNIC
was observed in four cross-sectional studies by different
groups that used variable test and conditioning stimuli
[31,32-34] (Table 5). Diminished DNIC has also been noted
in other types of chronic pain; that is, temporomandibular
disorder and hip osteoarthritis [35,36]. The normalization of
DNIC after hip osteoarthritis surgery suggests it may be an
objective measure of chronic pain that can change over time
with treatment [36].
Functional neural imaging
Functional neural imaging enables investigators to visualize
how the brain processes the sensory experience of pain. The
primary modes of functional imaging that have been used in
FM include functional magnetic resonance imaging (fMRI),
single-photon emission computed tomography (SPECT), and
positron emission tomography.

fMRI studies evaluating pain processing have the strongest
current evidence of the functional imaging studies, because
Page 3 of 18
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Table 2
Pressure pain thresholds in fibromyalgia

Year of
study

Number
of FM
patients

Number
of control
individuals

Staud and
colleagues [102]

2005

11

12

PPT: affected
and CP

ASC

Decreased PPT (opposite of HC) after exercise

Sandberg and
colleagues [103]

2005

19

19 HC, 7 TM

PPT: TP

ASC

FM, TM with decreased PPT

Montoya and
colleagues [104]

2005

12

12

PPT, ERP

ASC

No difference (trend toward FM with decreased
PPT). HC with decreased PPTs with repeat stimuli
in one session. Decreased PPT for left hand versus
right hand. FM decreased PPT in second
assessment period (after EEG)

Laursen and
colleagues [105]

2005 10 FM/whiplash,
2005
10 RA,
10 CLBP,
10 endometriosis

41

PPT: TP
and CP

ASC

FM/whiplash, RA, endometriosis, CLBP with
decreased PPT. Correlation between pressure
hyperalgesia at lowest PPT sites and physical
function impairment and mental health found

Landis and
colleagues [51]

2004

37

30

PPT: TP
and CP

ASC

FM women with decreased PPT. PPT correlated
with sleep spindle incidence and duration

Landis and
colleagues [106]

2004

33

37

PPT: TP

ASC

FM women with decreased PPT

Maquet and
colleagues [107]

2004

20

50 females,
50 males

PPT: TP

ASC

HC with decreased intraindividual variation (FM
w/24%). HC females with decreased PPT
compared with HC males. FM with decreased PPT
compared with HC females. No difference
between dominant and nondominant hands. PPT
reproducibility and discrimination optimal at gluteal
and knee

Geisser and
colleagues [108]

2003

20

20

PPT: TP
and CP

ASC

FM with decreased PPT (more statistically
significant than HPT). Catastrophizing correlated
with decreased PPT. Depression associated with
increased PPT

Yoldas and
colleagues [47]

2003

11

10

PPT and
ERP

ASC

FM reduced P300 amplitude, correlated well with
PPT

2003

18

n/a

PP: over
masseter

ASC

No difference (trend toward decreased
PPT after antagonist)

2002

145 (FM,
CFS, WP,
MPTE, MP)

22

PPT: CP and TP,
HPT, CPT, cold
pressor test,
ischemic tourniquet
test

ASC

FM with decreased PPT (CFS, MPTE), HPT (CFS),
cold pressor test (CFS), ischemic tourniquet test
(CFS, MPTE, WP, MP) than HC

Reference

Ernberg and
colleagues [109]
Carli and
colleagues [110]

QST

QST
method

Findings

Hedenberg2002
Magnusson and colleagues [111]

18

15 masseter
myalgia

PPT: over
masseter

ASC

Decreased PPT after treatment in both groups.
Correlated with symptoms

Ernberg and
colleagues [112]

12

12 HC,
12 RA

PPT: masseter

ASC

FM with decreased PPT

15 FM
ketamine
responders

Placebo

EPT, PPT:
TA muscle, PPT
and pain tolerance: 3 TPs

ASC

Increased PPT at TA muscle, pain pressure
tolerance after ketamine compared with placebo.
Noted improvement in symptoms

2000

Graven-Nielsen
2000
and colleagues [113]
Ernberg and
colleagues [114]

2000

12

12

PPT

ASC

FM with no significant increase in pain or decrease
in PPT. HC with increased pain and decrease in
PPT after infusion

Ernberg and
colleagues [115]

1999

18

10 HC, 17
local myalgia

PPT, pain
tolerance:
masseter

ASC

FM with decreased PPT associated with higher
fraction of masseter to serum serotonin levels
Continued overleaf
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Table 2
Continued

Year of
study

Number
of FM
patients

Number
of control
individuals

QST

QST
method

Kosek and
Hansson [30]

1997

10

10

PPT

ASC

FM decreased PPT

Kosek and
colleagues [31]

1996

10

10

PPT

ASC

FM decreased PPT

McDermid and
colleagues [116]

1996

20

20 HC,
20 RA

PPT: TP
and CP

ASC

FM decreased PT compared with RA, HC. RA
decreased PT compared with HC

Kosek and
colleagues [117]

1995

16

n/a

PPT at
cream site

ASC

No difference in PPT after EMLA cream

Tunks and
colleagues [118]

1995
1995

6

6 myofascial
6 pain controls,
6 HC

PPT: TP
and CP

ASC

FM and myofascial pain was discriminated from
HC by dolorimetry and palpation

Wolfe and
colleagues [119]

1995

391

n/a

TPC,
dolorimetry

ASC

PPT and TPC correlate with symptoms, but TPC
correlates better

Gibson and
colleagues [29]

1994

10

10

PPT: TP
and CP

ASC

FM decreased PPT at CT and TP, but data not
clearly shown

Lautenbacher and
colleagues [120]

1994

26

26

PPT: CP
and TP

ASC

FM decreased PPT

Granges and
Littlejohn [121]

1993

60

60

PPT: TP
and CP

ASC

FM decreased HPT, PPT, CPT in CP and TP

Lautenschlager and
colleagues [122]

1991

47

n/a

PPT: TP
and CP

ASC

Body diagram correlated better with dolorimetric
findings than visual analog scale

Reference

Findings

ASC, ascending; CFS, chronic fatigue syndrome; CLBP, chronic low back pain; CP, control point; CPT, cold pain threshold; CT, cold perception
threshold; EEG, electroencephalography; EMLA, local anesthetic cream; EPT, electrical pain threshold; ERP, event-related potential; FM, fibromyalgia; HC, healthy control individuals; HPT, heat pain threshold; MP, diffuse multiregional pain; MPTE, multiregional pain associated with at least
11 tender points; n/a, not applicable; PPT, pain pressure thresholds; QST, quantitative sensory testing; RA, rheumatoid arthritis; TA, tibialis
anterior; TM, temporal mandibular disorder; TP, tender point; TPC, tender point count; WP, widespread pain.

they corroborate this left-shift in stimulus–response function
(that is, hyperalgesia/allodynia) noted in FM. Specifically,
several areas of the brain consistently show greater activation
in FM patients than in control individuals given the same
objective stimulus intensity – especially the secondary
somatosensory cortex, insula and the anterior cingulate
cortex. These findings have been noted in five cross-sectional
studies by two different groups, using both pressure and heat
stimuli [37,38] (Table 6). In the study by Giesecke and
colleagues, the clinical pain intensity corresponded with an
increase in the evoked regional cerebral blood flow [37]. The
resting regional cerebral blood flow was evaluated by a third
group in a longitudinal study using fMRI, and showed change
after drug treatment [39]. These studies have also been
useful in identifying differences in pain processing in
individuals with and without psychological comorbidities,
showing for example that depression does not seem to be
influencing the magnitude of neuronal activation in sensory
pain regions such as the secondary somatosensory cortex,
whereas cognitive factors such as catastrophizing did
influence the sensory intensity of pain [37,40].

Positron emission tomography imaging in FM has been
reported in only a few studies with inconclusive results. The
only positive study is a recent one showing there may be
altered dopaminergic activity in FM [41].
SPECT imaging has been studied in four cross-sectional
studies by different groups that consistently found reduced
regional cerebral blood flow in the right thalamus of patients
with FM (three of the four studies) [42-45]. No correlation
between symptoms and findings were noted in the SPECT
studies.
The consistent abnormalities seen in fMRI and SPECT
studies suggest either of these methods might be useful to
use as a biomarker, but longitudinal studies showing that
improvements in symptoms coincide with normalization of
functional imaging findings would be necessary to establish
this role. The advantages of fMRI imaging over positron
emission tomography and SPECT include the less invasive
nature and the higher temporal and spatial resolutions of
fMRI. Disadvantages of fMRI include the cost and pracPage 5 of 18
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Table 3
Pain pressure thresholds and fibromyalgia (FM): part 2

Year of
study

Number of
FM patients

Number of
control
individuals

QST

QST method

Petzke and
colleagues [123]

2005

43

28

PPT: CP

ASC and
random

FM patients report greater pain intensity but
less relative unpleasantness compared with
HC

Giesecke and
colleagues [124]

2004

16

11 HC,
11 CLBP

PPT: CP

ASC and
random

FM and CLBP with decreased PPT

Giesecke and
colleagues [125]

2003

97

n/a

PPT: CP

ASC and
random

FM subgroups: high and low tenderness.
High or low control over pain correlated with
cognitive and mood factors

Petzke and
colleagues [28]

2003

43

28

PPT: CP,
suprathreshold

ASC and
random

FM decreased PPT, suprathresholds.
Ratings from random method were
consistently higher than those of the ASC
method, possibly due to perceived lack of
perceived control

Petzke and
colleagues [24]

2003

39 FM,
6 CWP,
3 regional

28 no pain,
3 pain

PPT: CP
and TP

ASC and
random

Random method independent of psychological
state. ASC correlated more with psychological
state

Gracely and
colleagues [126]

2002

16

16

PPT: CP

ASC and
random

FM with decreased PPT

Chang and
colleagues [27]

2000

11 IBS +
FM

11 IBS,
10 HC

PPT: TP
and CP

ASC and
random

In random method, IBS + FM with more
decreased PPT than IBS, but not HC. IBS with
higher PPT than HC. In ASC, IBS similar PPT
to HC

Bendtsen and
colleagues [127]

1997

25

25

PPT: TP
and CP,
suprathreshold

Random

FM with left shift in response
function for stimuli applied to tender point
(trapezius m) only, no difference in CP
compared with HC

Reference

Findings

ASC, ascending; CLBP, chronic low back pain; CP, control point; CWP, chronic widespread pain; HC, healthy control individuals; IBS, irritable
bowel syndrome; PPT, pain pressure thresholds; QST, quantitative sensory testing; TP, tender point.

ticability as well as the inability to perform receptor–ligand
studies that are possible with positron emission tomography
and SPECT.

Event-related potentials
Cerebral potentials evoked by noninvasive stimulation provide
a unique opportunity to investigate the functional integrity and
magnitude of brain processing pathways. Expressing the
ability of the human brain to discriminate, classify, and
memorize the significance of exogenous stimuli, event-related
potentials (ERPs) have been used as a marker of cognitive
function in patients with psychiatric and neurological
disorders. The electrical waveforms generated can be divided
into late and early components, and the waveforms are
designated by their polarity (P-positive, N-negative) and
latency (timing of peak) after stimulus onset. Additionally, the
amplitude – the size of the voltage difference between the
component peak and a prestimulus baseline – is also
quantified. Auditory, somatosensory, and visual ERPs have
been evaluated in patients with FM in a few studies.
Page 6 of 18
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Among the ERPs evaluated to date, the P300 potential (most
commonly generated by an auditory consciously attended
stimuli) appears to be the most promising to differentiate FM
patients from control individuals. The P300 wave is a late
cortical neuropsychological event, the latency of which
reflects the information processing speed and the amplitude
of which expresses memory functions. A reduced P300
amplitude during an auditory discriminated-task paradigm has
been significantly noted in FM patients as compared with
control individuals in three cross-sectional studies by two
different groups [46-48] (Table 7). All three studies also
evaluated the P300 latency, but only the largest study by
Alanoglu and colleagues noted an increase in P300 latency,
a finding that may have not been found in the prior studies
due to lack of power [46]. In the one of these three studies by
Ozgocmen and colleagues that performed ERPs before and
after treatment, 8 weeks of sertraline treatment led to an
increase in the P300 magnitude [48].
These studies generally failed to show an association
between the ERP findings and symptom severity, although

Available online http://arthritis-research.com/content/10/4/211

Table 4
Heat pain threshold, cold pain threshold, and electrical stimuli in fibromyalgia

Year of
study

Number
of FM
patients

Number
of control
individuals

Petzke and
colleagues [28]

2003

43

Gibson and
colleagues [29]

1994

Staud and
colleagues [102]

QST

QST
method

28

HPT,
suprathreshold

ASC and
RAN

FM decreased HPT, suprathresholds. Pain ratings
from RAN were consistently higher than ASC,
possibly due to perceived lack of perceived control

10

10

WT and
HPT

ASC and
RAN

FM decreased HPT, no difference in WT

2005

11

12

Suprathreshold:
affected and CP

ASC

Increased thermal pain ratings after exercise
(opposite of HC)

Geisser and
colleagues [108]

2003

20

20

HPT, WT

ASC

FM with decreased HPT. Higher intensity and
unpleasantness for non-noxious stimuli

Kosek and
Hansson [30]

1997

10

10

CT, WT,
CPT, HPT

ASC

FM decreased CT in forearm. FM decreased CPT
and HPT. No difference in WT

Lautenbacher and
Rollman [34]

1997

25

26

HPT

ASC

FM had decreased HPT

Kosek and
colleagues [31]

1996

10

10

CT, WT,
CPT, HPT

ASC

FM decreased HPT, CPT. FM had decreased WT
only at TP

Lorenz and
colleagues [128]

1996

10

10

HPT

ASC

FM decreased HPT

Lautenbacher and
colleagues [120]

1994

26

26

HPT

ASC

FM decreased HPT, no difference in WT

Lautenbacher and
Rollman [34]

1997

25

26

Electrical

ASC

No difference in electrical detection/PT

Lautenbacher and
colleagues [120]

1994

26

26

Electrical –
CP and TP

ASC

FM decreased electrocutaneous only at TP, not
control points

Arroyo and
Cohen [129]

1993

10

10

Electrical detection,
suprathreshold

ASC

No difference in electrical detection, FM
decreased electrical tolerance

Reference

Findings

ASC, ascending; CP, control point; CPT, cold pain threshold; CT, cold perception threshold; FM, fibromyalgia; HC, healthy control individuals;
HPT, heat pain threshold; PT, pain threshold; QST, quantitative sensory testing; RAN, random; TP, tender point; WT, warmth perception threshold.

Table 5
Diffuse noxious inhibitory controls (DNIC) in fibromyalgia (FM)
Number of
control
individuals

Test stimuli
(noxious stimuli)

Heterotopic
conditioning
noxious stimuli

Findings

30

30 HC,
30 CLBP

Water bath, cold,
noxious

Water bath, cold,
noxious

Diminished DNIC in FM patients, not
CLBP

2003

11

22 females,
11 males

Wind up

Water bath, heat,
noxious

Diminished DNIC in female HC and
female FM patients

1997

10

10

CT, WT, HPT, CPT

Tourniquet

Diminished DNIC in FM patients

Lautenbacher
1997
and Rollman [34]

25

26

Electrical pain
threshold

Thermode tonic
cold thermal, noxious
and non-noxious

Diminished DNIC in FM patients

Year of
study

Number of
FM patients

Julien and
colleagues [32]

2005

Staud and
colleagues [33]
Kosek and
Hansson [30]

Reference

Electrical detection

No difference

CLBP, chronic low back pain; CT, cold perception threshold; CPT, cold pain threshold; HC, healthy control individuals; HPT, heat pain threshold;
WT, warmth perception threshold.
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Table 6
Neural imaging in fibromyalgia (FM)

Year of
study

Number of
FM patients

Giesecke and
colleagues [37]

2005

7

Gracely and
colleagues [40]

2004

15 high
catastrophizers

Reference

Giesecke and
2004
colleagues [124]

Number of
control
individuals

Neural
imaging

Description

QST

Findings

fMRI

QST evoked
rCBF association
to depression

Pressure pain
MRS

Clinical pain intensity –
associated with increased rCBF
of insula bilaterally, contralateral
ACC, prefrontal cortex.
Symptoms of depression – not
associated with increased rCBF
of SI, SII; associated amygdala
and contralateral anterior insula

14 low
catastrophizers

fMRI

QST evoked
rCBF association
to catastrophizing

Pressure pain
MRS

Both low and high with increased
rCBF in contralateral insula, SI,
SII, inferior parietal lobule and
thalamus, ipsilateral S1,
cerebellum, posterior cingulate
gyrus, and superior and inferior
frontal gyrus. High catastrophizers
with unique activation in
contralateral anterior ACC,
contralateral ipsilateral lentiform

16

11 HC,
11 CLBP

fMRI

QST evoked
rCBF

Pressure pain
MRS

In CLBP and FM patients, QST
(equal pressure) increased rCBF
of contralateral SI and SII, inferior
parietal lobule, cerebellum, and
ipsilateral SII. In HC, QST (equal
pressure) activation of
contralateral SII. Equal evoked
equal pain associated with similar
activation

7 MDD/FM,
7 HC

Koeppe and
colleagues [39]

2004

?

None

fMRI

Injection of 5-HT-3 n/a
receptor antagonist
(topisetron) rCBF

In FM patients, topisetron
treatment reduced rCBF of SI,
contralateral posterior insula,
ACC

Cook and
colleagues [38]

2004

9

9 HC

fMRI

QST evoked
activation of rCBF

Nonpainful and
painful heat, 47°C

In FM, nonpainful heat increased
rCBF in prefrontal, supplemental
motor, insular, and ACC as
compared with HC. In FM
patients, painful heat increased
activity in contralateral insular
cortex as compared with HC

Gracely and
2002
colleagues [126]

16

16 HC

fMRI

QST evoked
activation of rCBF

Pressure pain
MRS, neutral site

Common areas of evoked equal
pain increased rCBF including
contralateral SI, inferior parietal
lobule, SII, superior temporal
gyrus (STG), insula, putamen, and
ipsilateral cerebellum. Decreased
rCBF in ipsilateral SI. In HC, QST
(equal pressure) activated
ipsilateral STG and precentral
gyrus

Yunus and
2004
colleagues [130]

12

7 HC

PET

Resting rCBF

n/a

No difference

Chang and
2003
colleagues [131]

10 IBS +
FM

10 IBS

PET

QST evoked
activation of rCBF

Noxious visceral
and somatic
pressure

In IBS patients, noxious visceral
stimuli evoked increased rCBF
increase in middle subregion of
the ACC. In IBS + FM patients,
somatic stimuli evoked greater
rCBF in middle subregion of the
ACC extending to ACC and the
thalamus
Continued overleaf
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Table 6
(Continued)

Number of
FM patients

Number of
control
individuals

Neural
imaging

Wik and
2006
colleagues [132]

8

None

Wood and
colleagues [41]

2007

11

Adiguzel and
colleagues [42]

2004

Gur and
colleagues [45]

Reference

Year of
study

Description

QST

Findings

PET

QST evoked
activation of rCBF

Acute pain

In FM patients, frontal and parietal
cortical activation during acute
pain compared with rest (as
expected). Reduced rCBF in
retrosplenial cortex (evaluative
processing)

11 HC

PET

QST evoked
binding of D2/D3
ligand

Nonpainful and
painful saline
injection

In FM patients, lack of dopamine
release in basal ganglia compared
with HC during painful stimuli. In
HC, amount of dopamine release
correlated with amount of
perceived pain; in FM patients, no
such correlation observed

14

None

SPECT

Amitriptyline
(3 months) resting
rCBF

n/a

Increased rCBF in bilateral
hemithalami after amitriptyline. No
correlation between symptoms
and findings

2002

19

20 HC

SPECT

Resting rCBF

n/a

Increased rCBF in caudate
nucleus. FM patients with less
depression had increased uptake
in pons

Kwiatek and
colleagues [43]

2000

17

22 HC

SPECT

Resting rCBF

n/a

Reduced rCBF in right thalamus
and potine tegmentum, no
reduction in left thalamus, or
caudate nucleus. No correlation
between symptoms and findings

Mountz and
colleagues [44]

1995

10

7 HC

SPECT

Resting rCBF

n/a

Reduced rCBF in bilateral
hemithalami and caudate nucleus
correlated with low pain threshold
No correlation between
symptoms and findings

ACC, anterior cingulate cortex; CLBP, chronic low back pain; fMRI, functional magnetic resonance imaging; HC, healthy control individuals;
5-HT-3, 5-hydroxytryptamine 3; IBS, irritable bowel syndrome; MDD, major depression disorder; MRS, multiple random staircase; n/a, not
applicable; PET, positron emission tomography; QST, quantitative sensory testing; rCBF, regional cerebral blood flow; SI, somatosensory cortex I;
SII, somatosensory cortex II; SPECT, single-photon emission computed tomography.

there was an association noted with the total myalgic score.
Although the change in the P300 potential after sertraline
treatment was attractive, the authors agreed that – given the
corresponding significant clinical improvement in pain,
fatigue, or depression – the mechanism for the change
remained unclear, and they acknowledged it may represent
regression to the mean. Larger studies by different groups
with an attention to standardizing methods are essential prior
to mainstream use of this marker.
In contrast to auditory potentials, there are few and varied
studies evaluating somatosensory and visual ERPs. The
assorted protocols used in the studies investigating somatosensory and visual ERPs may have contributed to the lack of
consistently demonstrated differences in FM and normal
individuals. The lack of an established standardized metho-

dology makes direct comparison difficult and may limit the
evidence of reproducibility.

Sleep and activity
In addition to pain, other symptoms very commonly seen in
FM include disturbed sleep and poor function. Sleep logs
and polysomnography have consistently confirmed patient
reports of hypersomnolence [49,50]. Using polysomnography, investigators have correlated hypersomnolence with
poor sleep quality by demonstration of fewer sleep spindles,
an increase in the cyclic alternating pattern rate, or poor
sleep efficiency [51-53]. Sleep abnormalities are rarely
shown to correlate with symptoms in FM, however, and many
investigators anecdotally feel as though even identifying and
treating specific sleep disorders often seen in FM patients
(for example, obstructive sleep apnea, upper airway resisPage 9 of 18
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Table 7
Evoked potentials in fibromyalgia (FM)

Year of
study

Number of
FM patients

Number of
control
individuals

Evoked
potential

Alanoglu and
colleagues [46]

2005

34

22

Yoldas and
colleagues [47]

2003

11

Ozgocmen and
colleagues [48]

2003

13

Reference

Paradigm

EP evaluated

Findings

Auditory

Auditory
discriminated
task paradigm

P300 wave

FM reduced P300 amplitude and
prolonged latency. No correlation
between EP findings, pain scores,
and quality of life measurements

10

Auditory

Auditory
discriminated
task paradigm

P300 wave

FM reduced P300 amplitude, but
no difference in potential latency.
P300 latency negatively
correlated with total myalgic
scores and the control point
scores. P300 amplitude
correlated with PPT and total
myalgic scores. No correlation in
amplitude or latency with
depression or anxiety.

10

Auditory

Auditory
discriminated
task paradigm ~
before and after
sertraline
treatment
(8 weeks)

P300 wave

FM reduced P300 amplitude, but
no difference in potential latency
at baseline. Sertraline treatment
resulted in increase in potential
amplitude by 8 weeks without
change in latency. No correlation
between EP findings, fatigue and
pain scores, but correlated to
total myalgic scores

EP, evoked potential; PPT, pain pressure thresholds.

tance, restless leg or periodic limb movement syndromes)
does not necessarily lead to improvements in the core
symptoms of FM.
Actigraphy
A method of motion assessment that infers sleep and
wakefulness from the presence of limb movements, actigraphy
is increasingly being used as a surrogate marker for both sleep
and activity. The actigraph typically combines a movement
detector and memory storage on a watch-like device. The
device can be worn on the wrist or the ankle continuously for
long periods of time. Sleep-pattern measures available via
actigraphy analyses include sleep latency, the wake time after
sleep onset, and the total sleep time; sleep architecture cannot
be measured, as with polysomnography. Compared with
polysomnography, however, actigraphy is less expensive, less
invasive, and more conducive to repeated measures, resulting
in extensive use in intervention studies [54].

Actigraphy is being increasingly used in FM studies and
appears promising, but has not yet proven adequately
sensitive to stand alone in clinical evaluation or treatment
trials [50,55,56]. As a measure of sleep quality there have
been inconsistent actigraphy results, with one group noting
increased levels of activity at night in FM (also noted in
patients with major depression) [55] and another group
Page 10 of 18
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noting no difference [50]. Edinger and colleagues used
actigraphy as an outcome measure in an intervention trial
comparing cognitive behavior therapy intervention with sleep
hygiene and usual care in the treatment of insomnia [57].
Deriving an actigraphic improvement criterion, the investigators showed a greater number of patients receiving
cognitive behavior therapy had clinically significant improvement in the total wake time compared with sleep hygiene
therapy. No statistical difference between cognitive behavior
therapy and usual care was able to be demonstrated, even
though a statistical difference between the groups was
shown using sleep log data in the same study.
As an objective measure of functional status, actigraphy
might hold more promise as a surrogate outcome measure,
because it allows the direct recording of activity levels, rather
than relying on patient self-report [58]. Kop and colleagues
demonstrated that although patients with FM have 36-Item
Short Form health survey scores nearly two standard
deviations below the population average, they have the same
average activity level as a group of sedentary control
individuals [58]. The FM patients had much lower peak
activity levels, however, suggesting that the problems in
function that FM patients report might be more due to an
inability to rise to the intermittent demands of day-to-day life
than due to overall reduced function.

Available online http://arthritis-research.com/content/10/4/211

Stress–response systems and
sex hormones
The theoretical link between stress–response systems and
symptom expression is supported by studies demonstrating
alterations of the hypothalamic–pituitary–adrenal axis and
the autonomic nervous system in FM. Probing different
aspects of the stress systems is underway to uncover
objective ways to identify persons at risk or to identify
reproducible abnormalities. One group clearly with
increased susceptibility is women. Investigators hypothesize
a potential effect of sex hormones on the stress response to
partly explain the female predominance seen in FM, but this
connection has not yet been specifically examined in FM
patients [59].
Hypothalamic–pituitary–adrenal axis
In basal and diurnal cortisol studies, the most consistently
found measure is a flattened diurnal plasma cortisol level
with an elevated trough, found in three of four crosssectional studies by two out of three groups [60-62]
(Table 8). Studies evaluating basal plasma cortisol levels,
salivary basal and diurnal cortisol levels, and urinary cortisol
levels have shown inconsistent results, but they generally
demonstrate normal to reduced basal levels. Since atypical
depression can show a reduced cortisol level, biopsychological factors that influence cortisol levels may be contributing to the inconsistent results currently found in the
literature [63]. These factors need to be better elucidated
and accounted for in future studies. Nonetheless, a flattened
diurnal cortisol level is a promising objective measure.

Evaluation of other components of the hypothalamic–pituitary–
adrenal axis has been relatively unrevealing. Basal and diurnal
adrenocorticotropic hormone shows no difference in FM
patients versus healthy control individuals [62,64,65]
(Additional file 1). Provocative hypothalamic–pituitary–adrenal
studies utilizing the cosyntropin test have shown inconsistent
results [62,66-68] (Additional file 2).
Results of the dexamethasone suppression test have been
reported in a number of studies by different groups, and the
results reveal normal to high levels of cortisol following
infusion of the corticosteroid [60,64,66,69,70] (Additional
file 3). Depression also typically follows a pattern of resistance to the dexamethasone test, and therefore is a
confounding factor in a large number of these evaluations.
Studies have also been completed to assess the cortisol
response to exogenous corticotropin-releasing hormone or
endogenous activators of corticotropin-releasing hormone
(that is, hypoglycemia, IL-6) in FM. Investigators found normal
to reduced cortisol levels in patients with FM after an
increase in corticotropin-releasing hormone, but these results
were not reproduced in other similar studies. Further investigation taking into account psychological factors as well as
doses of different drugs will be prudent.

Autonomic reactivity
Tilt table testing and heart rate variability have been evaluated
in patients with FM. The consistent and reproducible finding
of lower heart rate variability in FM patients compared with
control individuals (in three cross-sectional studies by two
different groups) makes it a more useful measure than tilt
table testing [71-73]. An abnormal drop in blood pressure or
an excessive rate of syncope during tilt table testing has been
noted in two out of three cross-sectional studies completed
by three different groups [74-76]. One study noted no
difference in normal individuals and control individuals using
univariate analysis [76]. Moreover, recent findings also
suggest that aberrations in heart rate variability may
predispose to fibromyalgia symptoms [77,78], possibly
identifying patients at risk.
Sex hormones
FM syndrome is more prevalent in women than in men,
suggesting a role of sex hormones in the pathophysiology of
FM [79]. To date, two studies have failed to show an
association between sex hormones and pain sensitivity
[79,80]. The reason for a female predominance in FM is
complex and warrants further investigation.

Serologic and biochemical abnormalities
Physicians from multiple disciplines have used simple blood
tests to diagnose and evaluate treatment for various
diseases. Scientists have similarly evaluated a number of
compounds in the serum and cerebrospinal fluid of patients
with FM to find a comparable marker of disease or disease
activity. Despite the effort to find easily accessible measures,
no clinically suitable tests have yet been appropriately
validated for FM.
Autoantibodies
The search for representative autoantibodies is a predictable
step for a disease like FM, often evaluated by rheumatologists and coexisting with autoimmune diseases. Antiserotonin antibody, antiganglioside antibody, and antiphospholipid antibody have been shown to be different in
FM patients and control individuals, but the applicability of
these findings is not yet clear [81] (Table 9). Antiserotonin
antibody has been shown to be increased in FM in three
cross-sectional studies by two different groups [81-83].
Antiganglioside antibody and antiphospholipid antibody have
each been shown to be increased in FM in two crosssectional studies by the same group [81,82]. A different
group evaluating antiganglioside antibody in a third crosssectional study was unable to reproduce the results [83].
Antithromboplastin antibody [83], antipolymer antibody [84],
and anti-68/48 kDa and anti-45kDa [85] have each been
evaluated in one cross-sectional study and have shown
increased levels in FM. A review of the literature demonstrates that antinuclear antibodies, antithyroid antibodies,
antisilicone antibodies, and antiglutamic acid decarboxylase
are not informative in FM.
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Table 8
Basal and diurnal cortisol and fibromyalgia (FM)

Year of
study

Number of
FM patients

Number of
control
individuals

1989

20

Crofford and
1994
colleagues [133]

7

Crofford and
colleagues [61]

2004

13

Adler and
colleagues [62]

1999

15

13

Korszun and
1999
colleagues [134]

9

Malt and
2002
colleagues [135]
Valkeinen and
2005
colleagues [136]

Reference
McCain and
Tilbe [60]

Griep and
colleagues [64]

1993

Gur and
2004
colleagues [137]

Measured (plasma)

Findings

20 RA

Plasma cortisol

Normal peak, elevated trough, flattened diurnal compared
to RA

7

Plasma cortisol

Normal peak, elevated trough, flattened diurnal

12 FMS + Plasma cortisol
CFS, 15 CFS

Delay in rate of decline in FM, elevated cortisol in late
period in FM, flattened diurnal, lower O/N cortisol in CFS

Plasma cortisol –
total and free

Normal, normal diurnal

9 HC,
8 CFS

Plasma cortisol

Normal

22

13

Plasma cortisol

Normal

13
(60 years
old)

13
(59 years
old)

Plasma cortisol

Normal

10

10

Plasma cortisol

Normal

63
(<35 years
old)

38
(<35 years
old)

Plasma cortisol

Reduced

Gur and
colleagues [63]

2004

68

46 HC,
62 CFS

Plasma cortisol

Reduced in FM with high BDI scores (>17), not in those
with low BDI. Reduced in CFS

Griep and
colleagues [66]

1998

40

14 HC,
28 CLBP

Plasma cortisol

Reduced

Lentjes and
1997
colleagues [138]

40

14 HC,
28 CLBP

Plasma cortisol –
total and free

Reduced total cortisol in FM only, Normal free cortisol in
FM, CLBP

Riedel and
colleagues [65]

1998

16

17

Plasma cortisol

Elevated

Catley and
2000
colleagues [139]

21

22 HC,
18 RA

Salivary cortisol
6 times/day

Elevated, normal diurnal

McClean and
2005
colleagues [140]

20

16

Salivary cortisol
5 times/day

Normal, normal diurnal strong relationship between current
pain symptoms and cortisol levels at waking and 1 hour
after waking. No relationship between fatigue and stress

Weissbecker
2006
and colleagues [141]

85

n/a

Salivary cortisol
6 times/day

Flattened diurnal, greater cortisol responses to awakening
in FM with history psychological, physical abuse

Dedert and
2004
colleagues [142]

91

n/a

Salivary cortisol
5 times/day

Flattened diurnal on those with low religiosity

Sephton and
2003
colleagues [143]

50

n/a

Salivary cortisol
5 times/day

Higher log-transformed mean salivary cortisols associated
with better memory

Adler and
colleagues [62]

15

13

24-hour urinary cortisol

Normal

Maes and
1998
colleagues [144]

?

PTSD,
depression

24-hour urinary cortisol

Normal

Torpy and
2000
colleagues [145]

13

8

24-hour urinary cortisol

Normal (trend toward reduced)

Crofford and
1994
colleagues [133]

12

10

24-hour urinary cortisol

Reduced (no difference between depressed and non
depressed)

Lentjes and
1997
colleagues [138]

40

14 HC,
28 CLBP

24-hour urinary cortisol

Reduced in FM and CLBP

Griep and
colleagues [66]

40

14 HC,
28 CLBP

24-hour urinary cortisol

Reduced

1999

1998

BDI, Beck Depression Inventory; CFS, chronic fatigue syndrome; CLBP, chronic low back pain; FMS, fibromyalgia syndrome; HC, healthy control
individuals; PTSD, post-traumatic stress disorder; RA, rheumatoid arthritis.
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Table 9
Autoantibodies and fibromyalgia (FM)

Reference
Klein and colleagues [82]

Klein and Berg [81]

Werle and colleagues [83]

Year of
study

Number of
FM patients

Number of
control individuals

1992

50

?HC

1995

2001

100

203

42 CFS, ?HC

64

Wilson and colleagues [84]

1999

47

16 OA,12 RA, banked sera,
15 myositis, 30 RA,
30 SLE, 30 SSc

Nishikai and colleagues [85]

2001

125

114 CFS, ?psych, ?CTD

Objective measure

Findings

Antiserotonin

Increased in FMS

Antiganglioside

Increased in FMS

Antiphospholipid

Increased in FMS

Antiserotonin

Increased in CFS and FMS

Antigangliosides

Increased in CFS and FMS

Antiphospholipid

Increased in CFS and FMS

Antiserotonin

Increased

Antithromboplastin

Increased

Antiganglioside

No difference

Gm1

No difference

Antipolymer antibody

Increased in antipolymer
antibodies, higher in severe
versus mild

Anti-68/48 kDa

Increased in FMS and CFS

Anti-45 kDa

Increased in FMS and CFS

CFS, chronic fatigue syndrome; CTD, connective tissue disease; FMS, fibromyalgia syndrome; HC, healthy control individuals; OA, osteoarthritis;
RA, rheumatoid arthritis; SLE, systemic lupus erythmatosus; SSc, systemic sclerosis.

The nonspecific increase in antibodies to a number of
antigens may be a nonspecific finding that arises from a
subtle shift in immune function in this spectrum of illness. In
the closely related chronic fatigue syndrome, investigators
have noted a shift from a T1 to a T2 immune response, which
would be expected to lead to increased production of
nonspecific antibodies. Any antibody or autoantibody
proposed as either a diagnostic test for FM or a biomarker of
FM must therefore be carefully tested using various control
individuals to ensure its authenticity.
Neuropeptides
Substance P is a neuropeptide released in spinal fluid when
axons are stimulated. Four different cross-sectional studies by
various groups in FM patients noted an elevation of
substance P in cerebrospinal fluid [86-89]. In contrast, a
normal substance P level has been noted in the cerebrospinal
fluid of patients with chronic fatigue syndrome [90]. Although
these results appear promising, elevated substance P is not
specific for FM but rather has been shown to occur in other
pain states such as chronic, daily headaches and chronic
neck or shoulder pain associated with whiplash injury
[91,92]. A high level of substance P therefore seems to be a
biological marker of the presence of chronic pain.

Nerve growth factor and calcitonin gene-related peptide are
additional neuropeptides that have been evaluated in FM.
Nerve growth factor was shown in one study to have

increased levels in FM and not in FM/rheumatoid arthritis
overlap, therefore presenting inconclusive results [93].
Cerebrospinal fluid and serum calcitonin gene-related
peptide have been studied and not found to be different in
FM patients and control individuals [94,95].
Biochemicals and cytokines
The amino acid tryptophan and the cytokine IL-8 have both
been shown to be different in patients compared with control
individuals in a couple of studies, but neither have been
evaluated in longitudinal studies [96-98]. A low tryptophan
level has been found in two of three studies by three different
groups [96,99,100]. IL-8 has been consistently demonstrated
in three studies by two different groups [97,98,101]. Moreover,
IL-8 has been shown to correlate with symptoms of FM and not
to be associated with depressed FM [98]. Serum IL-6 was
evaluated and found to be normal in FM patients [98,101].

Muscle abnormalities
Despite the interest and investigation for objective peripheral
muscle abnormalities, the results have remained variable and
have not yet been reproduced by different groups.
Additionally, there is great heterogeneity in the methods
evaluating for objective muscle abnormalities that render a
complete review of the data beyond the scope of the present
study. To dissect out possible useful objective measures,
further investigations are necessary, preferably utilizing noninvasive procedures.
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Table 10
Summary of findings for objective markers
Objective marker

Findings

Genetics

Polymorphisms in catecholamine o-methyl transferase have been noted in some ethnic groups but not others;
dopamine 4 receptor findings have not been replicated or refuted as compared with other polymorphisms

Tender point counts or index

Multiple studies suggesting utility. The tender point count and the tender point index may be influenced by
cognitive and emotional aspects of pain, and therefore may be biased

Pressure pain threshold

Multiple studies suggesting utility. The pressure pain threshold may be influenced by cognitive and emotional
aspects of pain, which may be minimized by utilizing a random pressure paradigm

Heat and cold pain threshold

Consistently different in patients versus control individuals but not shown to be correlated with changes in
clinical pain

Diminished diffuse noxious
inhibitory controls

Four cross-sectional studies by different groups suggest utility. Needs further exploration with standardized
methods, longitudinal studies

Functional neural imaging

Multiple studies suggesting utility. May be influenced by cognitive aspects of pain. Longitudinal studies
needed

Event-related potentials

Reduced P300 amplitude has been noted in three cross-sectional studies by two different groups. Larger
studies with standardized methods are necessary. Longitudinal studies needed

Sleep logs and polysomnography

Confirm reports of hypersomnolence, but no changes are pathognomonic of or specific for fibromyalgia

Actigraphy

Inconsistent measure of sleep quality. Report suggesting utility in measuring functional status. Larger,
longitudinal studies needed

Hypothalamic–pituitary–
adrenal axis

Flattened diurnal cortisol noted in three of four cross-sectional studies by two of three groups. Need to
explore influence of biopsychosocial factors. Longitudinal studies needed

Autonomic reactivity

Lower heart rate variability noted in three cross-sectional studies by two different groups. May predispose to
condition. Longitudinal studies needed

Autoantibodies

Antiserotonin antibody noted to be increased in three cross-sectional studies by two different groups.
Stringent controls necessary prior to determining utility. Longitudinal studies needed

Neuropeptides

Substance P noted to be increased in cerebrospinal fluid in four cross-sectional studies by various groups.
Potential nonspecific marker of chronic pain

Biochemical and cytokines

Low tryptophan and elevated IL-8 noted. Longitudinal studies needed

Muscle abnormalities

No clear and reproducible abnormality. Additional studies with standardized methods needed

Conclusion
Except for psychophysical pain testing, no objective measure
has been appropriately evaluated and shown to improve with
improvements in clinical status in a longitudinal study, and
thus to qualify as a biomarker (see Table 10 for summary).
These tests are not, however, entirely objective. Of the
objective tests, those that hold the most promise as
biomarkers are probably tests that directly assess elements
of neural function, such as functional neuroimaging, ERPs,

and DNIC. An effort by different groups to systematically
evaluate these measures in research trials to obtain useful,
comparable results will be vital for ongoing progress in
outcome research. There will be an ongoing need to identify
biomarkers for future studies that have reproducibility and
predictive value, practicability, and biological and temporal
relevance in FM.
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The following Additional files for this article are available
online:

This review is part of a series on
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Additional file 1 is an Excel file containing a table that
presents studies of basal and diurnal adrenocorticotropic
hormone and fibromyalgia. See http://arthritis-research.com/
content/supplementary/ar2443-s1.xls
Additional file 2 is an Excel file containing a table that
presents studies of the cosyntropin test and fibromyalgia.

Available online http://arthritis-research.com/content/10/4/211

See http://arthritis-research.com/content/supplementary/
ar2443-s2.xls
Additional file 3 is an Excel file containing a table that
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